Analysis

Analysis

Each piece reads a primary source and works out what it means for the record. We publish fewer rather than unsupportable, and never lead with press-release framing.

Trial update

What the TRG-035 Phase I record actually establishes

July 28, 2026 · Kitano Hospital (2024), trial announcement; Toregem BioPharma (2026), financing disclosure · anti-usag-1-trg035

The Phase I record shows a single ascending dose tolerated in adults. It says nothing about growing teeth in anyone, and the Phase II population is children with congenital agenesis, not adults.